- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03938753
Quality Control of CE-Certified Phonak Hearing Aids - 2018_42
May 3, 2019 updated by: Sonova AG
Phonak Hearing Systems pass through different development and study stages.
At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner.
If the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized.
Afterwards, and prior to product launch, the Phonak Hearing Systems undergo a final quality control in terms of clinical trials.
This is a pre-validation study, investigating optimized algorithms, features, functions and wearing comfort.
This will be a clinical evaluation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In this study one CE-labeled Phonak Receiver-in-the-canal (RIC) devices is investigated.
The experimental device will be investigated regarding Sound Quality perception ot the T-Coil program.
A secondary objective of this study is the investigation of the Overall system stability in daily life situations.
The experimental device contains direct connectivity functionality and a T-Coil.
The combination of a wireless chip for Bluetooth streaming and a T-Coil in one housing can cause audible artifacts on the T-Coil, which shall be investigated within this study.
This will be a clinical evaluation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zürich
-
Stäfa, Zürich, Switzerland, 8712
- Sonova AG
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult hearing impaired persons (minimum age: 18 years, moderate to severe Hearing loss)
- Good written and spoken (Swiss) German language skills
- Healthy outer ear
- Ability to fill in a questionnaire (p/eCRF) conscientiously
- Willingness to wear Receiver in the canal hearing aids
- Informed Consent as documented by signature
- Owning a compatible smartphone
Exclusion Criteria:
- Contraindications to the MD in this study, e.g. known hypersensitivity or allergy to the investigational product
- Limited mobility and not in the position to attend weekly appointments in Stäfa (Switzerland)
- Limited ability to describe listening impressions/experiences and the use of the hearing aid
- Inability to produce a reliable hearing test result
- Known psychological problems
- Central hearing disorders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phonak Audéo M90-T
The Phonak Audéo M90-T is a Receiver-in-the-canal Hearing aid with direct connectivity functionality and a T-Coil from Phonak which will be fitted to the participants individual Hearing loss.
|
Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective perception of the T-Coil Sound Quality
Time Frame: 4 weeks
|
The primary objective of this study is to measure that the overall sound Quality of the T-Coil program [subjective satisfaction rating on a scale from 0%-100% in 1% steps] of the investigational device is rated as at least as 60% or better [60% is the border between 'ok' and 'satisfied'] after a test period with daily life situations.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Program switch-back workflow into T-Coil program
Time Frame: 4 weeks
|
The number of incorrect switch-back occurences will be measured under laboratory conditions.
A switch-back workflow is defined as the correct (re)activation of the T-Coil program, after an automatic program change into a streaming program.
Due to an incoming phone call or due a start of audio streaming via Bluetooth, the investigational device will automatically switch into a streaming program.
As soon as the Bluetooth stream stops, the investigation device must automatically toggle back into the T-Coil program (switch-back workflow).
|
4 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Observation of the system stability
Time Frame: 4 weeks
|
Another objective of this study is the monitoring of the system stability during daily life situations.
The investigational device will be worn for 4 weeks in home trial.
Each investigational device will track the system stability in the background (unnoticeable for the HI-wearer).
A log file of the system stability can be read out by the investigator.
The system stability will be calculated by the amount of tracked system artefacts in relation to the overall wearing time.
System artefacts are not or only hardly noticeable for the HI wearer, so that these system artefacts can only be tracked by reading out the data logging of the investigational device.
|
4 weeks
|
Sound Quality rating of T-Coil program under lab conditions
Time Frame: 4 weeks
|
Another objective is the subjective perception of the Sound Quality of the T-Coil under laboratory condition.
Subjects will rate the perceived Sound Quality of an audio file streamed via T-Coil on a scale from 'not at all' to 'excellent'.
|
4 weeks
|
Subjective perception of audio artefacts in T-Coil program
Time Frame: 4 weeks
|
Another objective is to count the number of reports from subjects regarding audible artefacts in the T-Coil program after a home trial phase of 4 weeks.
Audible artefacts are defined as any disturbing unnatural sounds which interfere with a streamed signal via T-Coil.
Artefacts will be noted on a client questionnaire.
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 9, 2019
Primary Completion (Actual)
February 7, 2019
Study Completion (Actual)
February 28, 2019
Study Registration Dates
First Submitted
May 3, 2019
First Submitted That Met QC Criteria
May 3, 2019
First Posted (Actual)
May 6, 2019
Study Record Updates
Last Update Posted (Actual)
May 6, 2019
Last Update Submitted That Met QC Criteria
May 3, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Sonova2018_42
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hearing Loss
-
University of California, San FranciscoPatient-Centered Outcomes Research InstituteRecruitingHearing Loss | Hearing Loss, Sensorineural | Hearing Loss, Bilateral | Hearing Loss, Conductive | Hearing Loss, Noise-Induced | Hearing Loss, Unilateral | Hearing Loss, Mixed | Hearing Disorders in ChildrenUnited States
-
Oticon MedicalRecruitingEar Diseases | Hearing Loss, Conductive | Hearing Loss Mixed | Hearing Disability | Conductive Hearing Loss | Conductive Hearing Loss, Bilateral | Conductive Hearing Loss, UnilateralUnited Kingdom
-
MED-EL Elektromedizinische Geräte GesmbHCompletedHearing Loss | Hearing Loss, Sensorineural | Hearing Loss, Bilateral | Hearing Loss, Conductive | Hearing Loss, Unilateral | Hearing Loss, MixedAustria, Germany, United Kingdom
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompletedCochlear Hearing Loss | Sensorineural Hearing Loss, BilateralUnited Kingdom
-
Oticon MedicalCompletedConductive Hearing Loss | Conductive and Sensori-neural Hearing Loss in the Same Ear | Unilateral, Profound Sensori-neural Hearing LossUnited States
-
Frequency TherapeuticsCompletedHearing Loss, Sensorineural | Presbycusis | Noise Induced Hearing Loss | Sudden Hearing LossUnited States
-
Frequency TherapeuticsCompletedHearing Loss, Sensorineural | Noise Induced Hearing Loss | Sudden Hearing LossUnited States
-
Otologic Pharmaceutics, Inc.CompletedHearing Loss | Sensorineural Hearing Loss | Noise-Induced Hearing LossUnited States
-
Otologics LLCUnknownMixed Conductive and Sensorineural Hearing Loss, Bilateral
Clinical Trials on Audéo M90-T
-
Sonova AGCompletedHearing Loss | Sensorineural Hearing LossSwitzerland
-
Sonova AGCompletedHearing Loss, SensorineuralSwitzerland
-
Sonova AGCompletedHearing LossSwitzerland
-
Sonova AGCompletedHearing Loss, Bilateral Sensorineural, ProgressiveSwitzerland
-
Sonova AGCompleted
-
Sonova AGCompletedHearing Loss | Sensorineural Hearing LossSwitzerland
-
Sonova AGCompletedHearing Loss, SensorineuralSwitzerland
-
Sonova AGCompleted
-
Sonova AGCompleted
-
Sonova AGCompletedHearing Loss, Bilateral Sensorineural, ProgressiveSwitzerland